Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Edwin A. Basak"'
1
Akademický článek
The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
Autor: Edwin A. Basak, Karlijn de Joode, Tom J.J. Uyl, Ronald van der Wal, Marco W.J. Schreurs, Sjoerd A.A. van den Berg, Esther Oomen-de Hoop, Cor H. van der Leest, Layal Chaker, Richard A. Feelders, Astrid A.M. van der Veldt, Arjen Joosse, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Sander Bins
Publikováno v: Biomedicine & Pharmacotherapy, Vol 156, Iss , Pp 113839- (2022)
Introduction: Immune checkpoint inhibitor (ICI) associated diabetes is a harmful adverse event (AE) in patients with cancer following anti-programmed (cell) death protein-1 (PD-1) treatment. There are no available biomarkers able to predict this AE.
Externí odkaz: https://doaj.org/article/6bde66b85d864af29f569f89ed5b8a51
Zobrazit plný text záznamu
2
Akademický článek
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
Autor: Markus Joerger, Reno Debets, Edwin A. Basak, Daan P. Hurkmans, Cor H. van der Leest, Sebastiaan D.T. Sassen, Karlijn de Joode, Lisanne Putter, Annemarie J.M. Wijkhuijs, Birgit C.P. Koch, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and
Externí odkaz: https://doaj.org/article/91e30061d9b14b0499f8091d36100a62
Zobrazit plný text záznamu
3
Akademický článek
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Autor: Daan P. Hurkmans, Edwin A. Basak, Tanja van Dijk, Darlene Mercieca, Marco W. J. Schreurs, Annemarie J. M. Wijkhuijs, Sander Bins, Esther Oomen-de Hoop, Reno Debets, Markus Joerger, Arlette Odink, Astrid A. M. van der Veldt, Cor H. van der Leest, Joachim G. J. V. Aerts, Ron H. J. Mathijssen, Stijn L. W. Koolen
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against the curren
Externí odkaz: https://doaj.org/article/f8d983aed7774b85a3a382836c2bce1a
Zobrazit plný text záznamu
4
Akademický článek
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
Autor: Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts, Reno Debets
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for markers to stratify patie
Externí odkaz: https://doaj.org/article/85ac7d6b829b414e9203975733252de9
Zobrazit plný text záznamu
5
Akademický článek
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
Autor: Joachim G J V Aerts, Ron H J Mathijssen, Mandy van Brakel, Ellen Kapiteijn, Daan P Hurkmans, Els M E Verdegaal, Sabrina A Hogan, Rik de Wijn, Lies Hovestad, Dianne M A van den Heuvel, Rob Ruijtenbeek, Marij J P Welters, Edwin A Basak, Herbert M Pinedo, Cor H J Lamers, Harmen J G van de Werken, John P Groten, Mitchell P Levesque
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Many cancer patients do not obtain clinical benefit from immune checkpoint inhibition. Checkpoint blockade targets T cells, suggesting that tyrosine kinase activity profiling of baseline peripheral blood mononuclear cells may predict clini
Externí odkaz: https://doaj.org/article/fdec7b4cc229438683584ce62dfcc0e3
Zobrazit plný text záznamu
6
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment
Autor: Edwin A. Basak, Niels S. Vermeer, Karlijn de Joode, Daan P. Hurkmans, Dorian E.M. Velthuis, Esther Oomen-de Hoop, Marco W.J. Schreurs, Sander Bins, Stijn L.W. Koolen, Reno Debets, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Arjen Joosse, Ron H.J. Mathijssen
Publikováno v: European Journal of Cancer, 174, 113-120. Elsevier Ltd.
AIM: With increasing use of immune checkpoint inhibitors (ICIs) more patients will develop severe and potentially life-threatening immune-related adverse events (irAEs). So far, predictive models for the occurrence of grade ≥3 irAEs are lacking. Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::412001a708378502415a952c5d8415ce
https://doi.org/10.1016/j.ejca.2022.07.015
Zobrazit plný text záznamu
7
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
Autor: Birgit C. P. Koch, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Annemarie J.M. Wijkhuijs, Sebastiaan D.T. Sassen, Reno Debets, Edwin A. Basak, Cor van der Leest, Markus Joerger, Astrid A M van der Veldt, Lisanne Putter, Karlijn de Joode, Stijn L.W. Koolen, Daan P. Hurkmans, Marco W.J. Schreurs
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, 9(6):e002344. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
BackgroundDosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4041e49eb3f228636461cdfa0bf8425b
https://jitc.bmj.com/content/9/6/e002344.full
Zobrazit plný text záznamu
8
Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer
Autor: Astrid A M van der Veldt, Esther Oomen-de Hoop, Stijn L.W. Koolen, Daan P. Hurkmans, Ilse den Besten, Edwin A. Basak, Marco W.J. Schreurs, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Annemarie J.M. Wijkhuijs, Reno Debets, Stefan Sleijfer, Sander Bins
Publikováno v: European Journal of Cancer, 109, 12-20. Elsevier Ltd.
Introduction Nivolumab treatment is subject to large interpatient variability in both efficacy and toxicity, which may partly be explained by differences in nivolumab exposure. Exposure–response relationships in regular healthcare have not been ext
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa8136f63400117cbb3ee0e0e217110
https://doi.org/10.1016/j.ejca.2018.12.008
Zobrazit plný text záznamu
10
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
Autor: Samira El Bouazzaoui, Sander Bins, Astrid A M van der Veldt, Stefan Sleijfer, Ron H.N. van Schaik, Daan P. Hurkmans, Ron H.J. Mathijssen, Stijn L.W. Koolen, Joachim G.J.V. Aerts, Edwin A. Basak, Reno Debets, Cor van der Leest, Esther Oomen-de Hoop, Nina Schepers
Publikováno v: Journal for ImmunoTherapy of Cancer, 8(1):e000586. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundA minority of patients with advanced non-small-cell lung cancer (NSCLC) benefit from treatment with immune checkpoint inhibitors (ICIs). Ineffective effector function of activated T and NK cells may lead to reduced tumor cell death, even wh
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61be15f4ecb85bda87440d856f59f3b7
https://pure.eur.nl/en/publications/cdcdba93-ba5f-4fb5-8d11-fcca4546f7ee
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje